DNA strand with HER2 receptor

Decoding Breast Cancer: How BRCA Mutations and IGF-1R Expression Impact Treatment

Mira Elwood monogram
Mira Elwood in Health & Wellness October 2026 • 4 min read.

"Unlocking the link between genetic mutations, protein expression, and Trastuzumab sensitivity in HER2-positive breast cancer patients."


Breast cancer is a complex disease, and its treatment often requires a personalized approach. One area of intense research focuses on understanding how genetic mutations and protein expression within cancer cells can influence the effectiveness of targeted therapies. A recent study delved into the interplay between BRCA mutations and the expression of insulin-like growth factor receptor-1β (IGF-1Rβ) in HER2-positive breast cancer patients.

HER2-positive breast cancer is characterized by an overabundance of the HER2 protein, which promotes cancer cell growth. Trastuzumab, a monoclonal antibody, is a standard treatment that targets HER2. However, not all patients respond equally to Trastuzumab, prompting scientists to investigate factors that might affect its efficacy.

The study aimed to assess the combined impact of BRCA mutations (specifically BRCA1/2) and IGF-1Rβ expression on Trastuzumab sensitivity in patients with HER2-positive breast cancer. Researchers also sought to unravel the relationships between HER2 overexpression, BRCA mutations, and IGF-1R expression through pathway reconstruction analysis.

AI Search Multiple angles on this topic

BRCA-Related Treatment Considerations

Loss-of-function mutations in BRCA1 or BRCA2 can cause homologous recombination deficiency, leaving cancer cells reliant on lower-fidelity DNA repair pathways nature.com. The prevalence of HER2 amplification or protein overexpression in BRCA1/2-associated breast cancers is low link.springer.com. For patients with newly diagnosed breast cancer and BRCA1/2 mutations, breast-conserving therapy may be considered; the cited ASCO recommendations report local control of the index cancer similar to that in noncarriers ascopubs.org.

The BRCA Discovery Milestone

In December 1990, Mary Claire King’s group published an analysis of 23 extended families with a very high incidence of early-onset breast cancer intechopen.com. BRCA1 and BRCA2 mutations are associated with increased risks of breast and ovarian cancer, and one source reports breast cancer risk of up to 85% in some cases ebsco.com. A 2023 historical review also describes BRCA mutations as significantly associated with breast and ovarian cancer by age 70 researchgate.net.

BRCA Mutations, IGF-1R Expression, and Trastuzumab Response: What the Study Revealed

DNA strand with HER2 receptor

The study analyzed data from 35 patients with HER2-positive breast cancer who were treated with Trastuzumab, either as an adjuvant/neoadjuvant therapy (82.9%) or after the development of metastasis (17.1%). The researchers performed immunohistochemistry to assess the expression of HER2, ER/PR, Ki67, and IGF-R1β. Bioinformatic analysis was then used to identify potential correlations between HER2 overexpression, BRCA mutations, and IGF-1Rβ expression.

Key findings from the study include:

  • High Prevalence of BRCA Mutations: 19 tumors (54%) presented BRCA mutations, with 11 (57.9%) being pathogenic.
  • IGF-1Rβ Expression and BRCA Status: Patients with BRCA mutations showed significantly higher IGF-1Rβ expression compared to those without (78.6% vs. 26.7%, p = 0.027).
  • Progression-Free Survival (PFS): The median PFS was 15.1 months in the overall population but shorter (9.7 months) in patients harboring BRCA mutations.
  • Disease-Free Survival (DFS): Patients with HER2-positive tumors and BRCA mutations had a median DFS of 60.3 months, while those without BRCA mutations had not reached that point (p = 0.018). A trend toward longer DFS was observed in HER2+ BRCA2 vs BRCA1 mutated patients.
  • IGF-R1β Expression and DFS: Patients with IGF-R1β-positive tumors treated with adjuvant/neoadjuvant Trastuzumab had a median DFS of 92.4 months, compared to those with IGF-R1β-negative tumors (p = 0.234).
AI Search Multiple angles on this topic

miRNA Signatures and HER2-Targeted Therapy

A review of microRNAs in breast tumor classification and pathogenesis reports that an early-stage or metastatic subset of HER2-positive, BRCA-positive patients has shown sensitivity to trastuzumab-targeted therapy doi.org. The review also describes miRNA signatures as an alternative means of detecting breast cancer samples harboring BRCA mutations doi.org. These findings are presented as reported observations in a subset, rather than as a general treatment outcome for all patients with both markers.

The study also reconstructed the signaling pathways involved, revealing that BRCA1 mutations may lead to IGF-1R overexpression and increased phosphorylation of AKT. This, in turn, affects the transcription factor YB-1, which translocates to the nucleus, binds to the HER2 promoter, and increases HER2 and EGFR expression.

Implications for Personalized Treatment

These findings suggest that BRCA mutational status and IGF-1R expression are linked to Trastuzumab sensitivity in HER2-positive breast cancer. This highlights the potential for personalized treatment strategies based on a patient's unique genetic and protein expression profile.

AI Search Multiple angles on this topic

HER2-Positive Disease and BRCA Mutations

HER2-positive breast cancers are uncommonly reported in patients with pathogenic BRCA1/2 variants, and available data on BRCA/HER2 co-alterations remain limited sciencedirect.com. A 2022 study found that co-occurring BRCA mutations and HER2-positive status correlated with worse survival after adjustment for prognostic variables (HR 3.4; 95% CI 1.3–16.7) thebreastonline.com. The study concluded that this co-occurrence was a poor prognostic factor in early or locally advanced breast cancer thebreastonline.com.

Emerging HER2 Treatment Directions

A review by Swain et al. describes the current standard of care for HER2-positive breast cancer, mechanisms of drug resistance, and next-generation platforms and therapies under consideration nature.com. A separate review notes that HER2 overexpression or amplification is found in 15–20% of invasive breast cancers and describes continuing research in molecular biology and drug development pmc.ncbi.nlm.nih.gov. Research on inherited BRCA mutations has also reported a strong association between germline BRCA2 mutations and acquired loss of RB1, a tumor suppressor linked in the source to resistance to CDK4/6 inhibitors in hormone receptor-positive, HER2-negative breast cancer targetedonc.com.

Surgical Decisions in Hereditary Breast Cancer

The optimal surgical treatment for operable breast cancer in BRCA1/2 mutation carriers depends on several factors and remains debated pmc.ncbi.nlm.nih.gov. Breast-conserving surgery is described as the preferred surgical treatment for early-stage sporadic breast cancer, while its oncological safety in BRCA1/2 mutation carriers has not been extensively studied pmc.ncbi.nlm.nih.gov. This leaves uncertainty in applying the standard approach for sporadic disease to carriers.

Prognostic Implications for Patients

In patients with early or locally advanced breast cancer, a study found that co-occurring BRCA mutations and HER2-positive status correlated with worse survival after adjustment for prognostic variables (HR 3.4; 95% CI 1.3–16.7) thebreastonline.com. The study concluded that this combination was a poor prognostic factor thebreastonline.com. The reported association offers a clinically relevant perspective on the outcomes described for this patient group.

For example, patients with BRCA mutations and high IGF-1R expression may benefit from alternative treatment approaches or combination therapies that target both HER2 and IGF-1R pathways. Further research is needed to validate these findings and explore the clinical utility of assessing BRCA and IGF-1R status in HER2-positive breast cancer.

By understanding the complex interplay between genetic mutations, protein expression, and treatment response, healthcare professionals can move closer to tailoring breast cancer treatments to individual patients, ultimately improving outcomes and quality of life.

How other sources qualify the treatment link

A separate source reports that HER2-positive cell lines became more responsive to trastuzumab when IGF1R was inhibited. Because this result comes from cell lines, it describes a laboratory response rather than patient outcomes.[1]

In a reported group of patients with HER2-positive breast cancer and germline BRCA mutations, five-year recurrence-free and overall survival were similar to those in noncarriers. This offers a different clinical comparison from the review’s report of sensitivity in a subset, without resolving how the findings relate across patient groups.[2] [3]

A single-institution series reported HER2 positivity in a minority of first breast cancers among BRCA1/2 carriers, with different rates reported for BRCA1 and BRCA2 carriers. This is context for how uncommon the HER2-positive setting may be in that series, not a measure of trastuzumab response.[4]

What remains unclear about IGF-1R and treatment response

  • Does the modeled link between BRCA1 mutations, IGF-R1β, and HER2 or EGFR expression translate into a treatment-response pattern in patients, given the clinical analysis that found IGF-1R expression was not predictive?[3] [5]
  • How should the reported trastuzumab sensitivity in a subset be reconciled with the survival comparison that found similar outcomes for BRCA carriers and noncarriers? The sources describe different patient comparisons and endpoints.[2] [3]

Terms used in the evidence

siRNA
A method used to inhibit IGF1R expression in the reported cell-line experiments.[1]
Postreceptor-signaling pathways
Signaling pathways shared by HER2 and IGF-1R after receptor activation.[5]

Sources

  1. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. (pubmed.ncbi.nlm.nih.gov)
  2. Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations. (pubmed.ncbi.nlm.nih.gov)
  3. MicroRNAs in Molecular Classification and Pathogenesis of Breast Tumors (2021)
  4. Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysis (pmc.ncbi.nlm.nih.gov)
  5. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer. (pubmed.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1093/annonc/mdw337.19, Alternate LINK

Title: Brca Mutations And Igf-R1 Expression In Modulating Sensitivity To Trastuzumab In Patients With Her2-Positive Breast Cancer

Subject: Oncology

Journal: Annals of Oncology

Publisher: Elsevier BV

Authors: M. Pistelli, A. Santinelli, M. Santoni, F. Piva, F. Bianchi, T. Biscotti, L. Belvederesi, Z. Ballatore, G. Occhipinti, M. De Lisa, A. Pagliacci, N. Battelli, R. Bracci, E. Maccaroni, L. Bastinelli, L. Cantini, R. Berardi, S. Cascinu

Published: 2016-09-01

Everything You Need To Know

1

What role do BRCA mutations play in treating HER2-positive breast cancer?

BRCA mutations, specifically BRCA1/2, are genetic alterations that can affect the response to cancer treatments. In the context of HER2-positive breast cancer, the study found that a significant portion of patients (54%) had BRCA mutations. These mutations were associated with higher expression of IGF-1Rβ and shorter progression-free survival when treated with Trastuzumab, a medication used to treat HER2-positive breast cancer. The presence of BRCA mutations can impact the effectiveness of the treatment and, thus, influence the course of the disease.

2

How does IGF-1R expression affect treatment outcomes?

IGF-1R, or Insulin-like Growth Factor Receptor-1β, is a protein that can influence cancer cell behavior. The study revealed a link between IGF-1Rβ expression and BRCA status in patients with HER2-positive breast cancer. Patients with BRCA mutations exhibited higher IGF-1Rβ expression. This is significant because the level of IGF-1Rβ expression was associated with how well patients responded to Trastuzumab. The study suggests that high IGF-1Rβ expression may be related to decreased sensitivity to Trastuzumab, potentially due to the signaling pathways that IGF-1Rβ activates.

3

What is the role of Trastuzumab in the treatment of HER2-positive breast cancer?

Trastuzumab is a monoclonal antibody used to treat HER2-positive breast cancer. It works by targeting the HER2 protein, which is overexpressed in these types of cancers and promotes cell growth. While Trastuzumab is an effective treatment, not all patients respond in the same way. The research showed that patients with BRCA mutations and/or high IGF-1Rβ expression had a different response to Trastuzumab compared to those without these characteristics. The study looked at Progression-Free Survival (PFS) and Disease-Free Survival (DFS) as indicators of Trastuzumab's effectiveness. Understanding the impact of BRCA mutations and IGF-1R expression on Trastuzumab response is vital for personalizing treatment plans.

4

Why is personalized treatment important based on the findings of this study?

The study's findings point towards the importance of personalized treatment strategies in HER2-positive breast cancer. This means that treatment plans should be tailored to each patient's unique genetic and protein expression profile. The results showed that patients' BRCA mutational status and IGF-1R expression are linked to their response to Trastuzumab, a key medication for this type of cancer. This information enables doctors to make more informed decisions about the most appropriate course of treatment, potentially improving outcomes by using therapies tailored to the patient's specific cancer.

5

How are BRCA mutations, HER2 expression, and IGF-1R expression connected in this context?

The study reconstructed signaling pathways, suggesting how BRCA mutations, HER2, and IGF-1R are interconnected. BRCA1 mutations may lead to increased IGF-1R expression and activation of the AKT pathway. This, in turn, can affect the transcription factor YB-1, which then binds to the HER2 promoter, boosting HER2 and EGFR expression. This provides a mechanistic explanation for how BRCA mutations might lead to resistance to Trastuzumab, as they can influence the expression of HER2, the target of the drug. These findings are important for understanding how different factors interplay in cancer progression and treatment resistance.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.